← Autonomix Medical, Inc. Common Stock overview

Autonomix Medical, Inc. Common Stock vs Inspire Medical Systems: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Autonomix Medical, Inc. Common Stock (AMIX)

Q3 2026
▲2

Autonomix's patent wins and cash raises drive volatile AMIX surge

  • New patents expand nerve-targeting platform Autonomix won three new US patents: overactive bladder diagnosis/treatment, autonomic nervous system assessment, and nerve-targeting cancer technology. These broaden its nerve-sensing platform into urology and oncology, boosting the long-term potential of its technology and supporting investor optimism.

    Patent wins are a core new driver of AMIX's growth story and stock interest.

  • Warrant deals bring in $7.5 million cash Autonomix raised about $2.6 million in July and $4.9 million in August by getting investors to exercise old warrants early. This cash strengthens the company's finances and funds operations, which reduces the risk of running out of money and supports the stock price.

    These capital raises directly improve AMIX's liquidity and are a major reason for the recent price jump.

  • Preclinical renal denervation data met with sell-off Autonomix reported positive preclinical results for its nerve-sensing platform in renal denervation, but the stock fell 16% that day. The drop shows investors may have already expected good news or worried about the cost of future studies, a reminder that clinical progress can still bring sharp pullbacks.

    This event shows the market's mixed reaction to pipeline news and is a real counterweight to the positive patent and cash stories.

August 2026
▲2

Autonomix's patent wins and cash raises drive volatile AMIX surge

  • New patents expand nerve-targeting platform Autonomix won three new US patents: overactive bladder diagnosis/treatment, autonomic nervous system assessment, and nerve-targeting cancer technology. These broaden its nerve-sensing platform into urology and oncology, boosting the long-term potential of its technology and supporting investor optimism.

    Patent wins are a core new driver of AMIX's growth story and stock interest.

  • Warrant deals bring in $7.5 million cash Autonomix raised about $2.6 million in July and $4.9 million in August by getting investors to exercise old warrants early. This cash strengthens the company's finances and funds operations, which reduces the risk of running out of money and supports the stock price.

    These capital raises directly improve AMIX's liquidity and are a major reason for the recent price jump.

  • Preclinical renal denervation data met with sell-off Autonomix reported positive preclinical results for its nerve-sensing platform in renal denervation, but the stock fell 16% that day. The drop shows investors may have already expected good news or worried about the cost of future studies, a reminder that clinical progress can still bring sharp pullbacks.

    This event shows the market's mixed reaction to pipeline news and is a real counterweight to the positive patent and cash stories.

Latest
▲2

Autonomix's patent wins and cash raises drive volatile AMIX surge

  • New patents expand nerve-targeting platform Autonomix won three new US patents: overactive bladder diagnosis/treatment, autonomic nervous system assessment, and nerve-targeting cancer technology. These broaden its nerve-sensing platform into urology and oncology, boosting the long-term potential of its technology and supporting investor optimism.

    Patent wins are a core new driver of AMIX's growth story and stock interest.

  • Warrant deals bring in $7.5 million cash Autonomix raised about $2.6 million in July and $4.9 million in August by getting investors to exercise old warrants early. This cash strengthens the company's finances and funds operations, which reduces the risk of running out of money and supports the stock price.

    These capital raises directly improve AMIX's liquidity and are a major reason for the recent price jump.

  • Preclinical renal denervation data met with sell-off Autonomix reported positive preclinical results for its nerve-sensing platform in renal denervation, but the stock fell 16% that day. The drop shows investors may have already expected good news or worried about the cost of future studies, a reminder that clinical progress can still bring sharp pullbacks.

    This event shows the market's mixed reaction to pipeline news and is a real counterweight to the positive patent and cash stories.

Inspire Medical Systems Inc (INSP)

Q3 2026
▲4

Inspire's reimbursement fix and raised guidance drive the story

  • New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.

    This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.

  • Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.

    The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.

  • Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.

    This explains the operational response to the reimbursement disruption and how the company plans to restore growth.

  • Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.

    These are secondary but supportive signals of governance and relative performance that round out the picture.

August 2026
▲4

Inspire's reimbursement fix and raised guidance drive the story

  • New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.

    This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.

  • Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.

    The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.

  • Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.

    This explains the operational response to the reimbursement disruption and how the company plans to restore growth.

  • Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.

    These are secondary but supportive signals of governance and relative performance that round out the picture.

Latest
▲4

Inspire's reimbursement fix and raised guidance drive the story

  • New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.

    This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.

  • Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.

    The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.

  • Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.

    This explains the operational response to the reimbursement disruption and how the company plans to restore growth.

  • Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.

    These are secondary but supportive signals of governance and relative performance that round out the picture.